Prospects and progress of antibody-drug conjugates in solid tumor therapies.
about
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.DNA damaging agent-based antibody-drug conjugates for cancer therapy
P2860
Prospects and progress of antibody-drug conjugates in solid tumor therapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Prospects and progress of antibody-drug conjugates in solid tumor therapies.
@en
type
label
Prospects and progress of antibody-drug conjugates in solid tumor therapies.
@en
prefLabel
Prospects and progress of antibody-drug conjugates in solid tumor therapies.
@en
P2093
P2860
P1476
Prospects and progress of antibody-drug conjugates in solid tumor therapies.
@en
P2093
David M Goldenberg
Robert M Sharkey
Serengulam V Govindan
P2860
P304
P356
10.1517/14712598.2016.1173203
P407
P577
2016-04-04T00:00:00Z